Behnaz Esmaeili

Behnaz Esmaeili practices at Harborview Medical Center in Seattle, Washington, part of University of Washington.

Behnaz Esmaeili's NPI, 1487066627, was assigned on May 22, 2014. Behnaz Esmaeili graduated from Tehran University of Medical Sciences School of Medicine in 2009. Behnaz Esmaeili holds Washington license MD61066137.

Behnaz Esmaeili's primary practice is Harborview Medical Center, at 325 9th Avenue, Seattle, WA 98104 in King County. The practice phone is (206) 744-9535.

Behnaz Esmaeili's primary practice is Harborview Medical Center in Seattle, Washington, part of University of Washington. Behnaz Esmaeili is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Behnaz Esmaeili to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Behnaz Esmaeili practices, 3 sites in all. Vendor and product names are available with a free account.

Epilepsy is Behnaz Esmaeili's primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Behnaz Esmaeili is board certified in epilepsy by the American Board of Psychiatry and Neurology. Dmand AI has Behnaz Esmaeili's licenses on file in 2 states: Washington and Massachusetts.

Dmand AI lists epilepsy and seizures among the conditions Behnaz Esmaeili treats.

CMS data shows 141 Medicare services from Behnaz Esmaeili across 4 procedure codes in 2024, for 94 Medicare patients. Medicare paid $13,639 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 94 Medicare patients who saw Behnaz Esmaeili in 2024. The largest group is 65 to 74, with 37 patients. 66% of them have high blood pressure, and 56% have high cholesterol. 45% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Behnaz Esmaeili's median patient age at 44, with 46% women.

In 2024, Behnaz Esmaeili wrote 875 Medicare Part D claims for 124 patients. 92% of them were for generic drugs. CMS names the drug for 781 of them, across 21 drugs with 11 or more claims each, at $68,743 in total drug cost. In 2023, CMS named 1,103 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Behnaz Esmaeili for performance year 2024, reported through an alternative payment model (APM). Behnaz Esmaeili accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Behnaz Esmaeili as offering telehealth.

Dmand AI links 23 papers to Behnaz Esmaeili, published from 2007 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Epilepsy, Seizures and Sudden Unexpected Death in Epilepsy. Behnaz Esmaeili has published most often in Epilepsy Behav. Behnaz Esmaeili's most frequent co-authors are Andrew Lin Ko, MD, Steven D. Tobochnik, MD and Ayham Alkhachroum, MD.

CMS Open Payments shows 1 general payment to Behnaz Esmaeili from 1 drug or device company in 2021. Education make up the largest share, 100% of the total. Zogenix Inc. paid the most, $13.

Behnaz Esmaeili graduated from Tehran University of Medical Sciences School of Medicine in 2009.

Behnaz Esmaeili is in network with 17 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.